mbi-226 has been researched along with Bacteremia* in 1 studies
1 review(s) available for mbi-226 and Bacteremia
Article | Year |
---|---|
MBI-226. Micrologix/Fujisawa.
Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated. Topics: Administration, Topical; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteremia; Catheterization, Central Venous; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Skin Absorption; Structure-Activity Relationship | 2003 |
1 trial(s) available for mbi-226 and Bacteremia
Article | Year |
---|---|
MBI-226. Micrologix/Fujisawa.
Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated. Topics: Administration, Topical; Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteremia; Catheterization, Central Venous; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Skin Absorption; Structure-Activity Relationship | 2003 |